Everence Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Everence Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.91M	Hold	4,274	–	–	0.12%	148
2025 Q4	$1.94M	Hold	4,274	–	–	0.11%	138
2025 Q3	$1.67M	Sell	4,274 -790	-16%	-$330K	0.1%	158
2025 Q2	$2.25M	Hold	5,064	–	–	0.15%	127
2025 Q1	$2.46M	Hold	5,064	–	–	0.17%	113
2024 Q4	$2.04M	Sell	5,064 -280	-5%	-$130K	0.13%	127
2024 Q3	$2.48M	Hold	5,344	–	–	0.16%	114
2024 Q2	$2.1K	Hold	5,344	–	–	0.15%	129
2024 Q1	$2.23K	Hold	5,344	–	–	0.15%	130
2023 Q4	$2.17M	Sell	5,344 -2,980	-36%	-$1.1M	0.16%	122
2023 Q3	$2.9K	Hold	8,324	–	–	0.22%	88
2023 Q2	$2.69M	Hold	8,324	–	–	0.22%	89
2023 Q1	$2.62K	Sell	8,324 -2,490	-23%	-$747K	0.21%	95
2022 Q4	$3.12K	Buy	10,814 +4,030	+59%	+$1.23M	0.27%	73
2022 Q3	$1.96M	Hold	6,784	–	–	0.18%	101
2022 Q2	$1.91M	Buy	6,784 +1,080	+19%	+$289K	0.17%	110
2022 Q1	$1.49M	Sell	5,704 -1,570	-22%	-$373K	0.11%	147
2021 Q4	$1.6M	Hold	7,274	–	–	0.12%	154
2021 Q3	$1.32M	Buy	7,274 +1,570	+28%	+$307K	0.11%	161
2021 Q2	$1.15M	Hold	5,704	–	–	0.09%	182
2021 Q1	$1.23M	Hold	5,704	–	–	0.11%	157
2020 Q4	$1.35M	Hold	5,704	–	–	0.13%	133
2020 Q3	$1.55M	Sell	5,704 -180	-3%	-$49.7K	0.17%	107
2020 Q2	$1.69M	Hold	5,884	–	–	0.2%	91
2020 Q1	$1.4M	Hold	5,884	–	–	0.2%	86
2019 Q4	$1.29M	Hold	5,884	–	–	0.19%	112
2019 Q3	$997K	Hold	5,884	–	–	0.16%	129
2019 Q2	$1.08M	Hold	5,884	–	–	0.18%	125
2019 Q1	$1.08M	Hold	5,884	–	–	0.19%	114
2018 Q4	$975K	Hold	5,884	–	–	0.23%	114
2018 Q3	$1.13M	Hold	5,884	–	–	0.23%	117
2018 Q2	$1M	Hold	5,884	–	–	0.21%	127
2018 Q1	$959K	Hold	5,884	–	–	0.21%	128
2017 Q4	$882K	Sell	5,884 -1,128	-16%	-$167K	0.19%	132
2017 Q3	$1.07M	Hold	7,012	–	–	0.24%	119
2017 Q2	$904K	Hold	7,012	–	–	0.22%	130
2017 Q1	$767K	Hold	7,012	–	–	0.2%	143
2016 Q4	$517K	Hold	7,012	–	–	0.15%	182
2016 Q3	$612K	Hold	7,012	–	–	0.18%	157
2016 Q2	$603K	Buy	7,012 +1,520	+28%	+$131K	0.19%	157
2016 Q1	$437K	Hold	5,492	–	–	0.14%	199
2015 Q4	$691K	Buy	5,492 +1,410	+35%	+$170K	0.22%	135
2015 Q3	$425K	Hold	4,082	–	–	0.15%	189
2015 Q2	$504K	Hold	4,082	–	–	0.16%	182
2015 Q1	$488K	Hold	4,082	–	–	0.16%	182
2014 Q4	$485K	Hold	4,082	–	–	0.17%	177
2014 Q3	$382K	Hold	4,082	–	–	0.14%	194
2014 Q2	$386K	Hold	4,082	–	–	0.14%	197
2014 Q1	$289K	Hold	4,082	–	–	0.11%	220
2013 Q4	$303K	Buy	+4,082	New	+$284K	0.12%	210

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Everence Capital Management's VRTX Position: Q1 2026 in Review

Everence Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 4,274 shares worth $1.91M. The position accounts for 0.12% of the portfolio, ranked #148.

Everence Capital Management first reported a position in VRTX in Q4 2013 and has held it in 50 quarters since. The position peaked at $2.69M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Everence Capital Management held 4,274 shares of Vertex Pharmaceuticals worth $1.91M as of Q1 2026.
Everence Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.12% of Everence Capital Management's portfolio in Q1 2026, its #148 holding.
Everence Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
Everence Capital Management's Vertex Pharmaceuticals position peaked at $2.69M in Q2 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.